Investment firms Panakes Partners, INKEF Capital and SHS Gesellschaft led the $30m round in Salvia BioElectronics, a neurostimulation platform company targeting chronic migraine. "We are delighted to welcome our new investors, and I would like to thank our existing investors for their continued support. This strong syndicate of highly renowned medical technology investors validates our approach and the funding enables us to complete our therapy development towards market entry," Hubert Martens, Salvia BioElectronic CEO.